Clinical trial · Interventional
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
NCT01734564CI-TRIAL-00026920completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this phase II study, patients with solid tumors will receive treatment with hiltonol and autologous dendritic cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hiltonol and autologous dendritic cells | Biological | — | UNRESOLVED |
| Hiltonol, dendritic cells and radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hiltonol and autologous dendritic cells
- description
- Hiltonol and autologous dendritic cells
- interventionNames
- Biological: Hiltonol and autologous dendritic cells
- type
- EXPERIMENTAL
- label
- Hiltonol, dendritic cells and radiation
- description
- Hiltonol, dendritic cells and radiation.
- interventionNames
- Radiation: Hiltonol, dendritic cells and radiation
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 8-10 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of advanced solid tumors * Measurable disease * Performance status 0, 1 or 2. * Adequate renal, hepatic and bone marrow function * Availability of tumor tissue, for maturing dendritic cells Exclusion Criteria: * Clinically relevant diseases or infections. * concurrent participation in other clinical trial or administration or other antitumoral treatment * Concurrent cancer, with the exceptions allowed by the PI. * Pregnant or breast feeding women * immunosuppressant treatment * known uncontrolled central nervous system metastasis
References
Publications (0)
Data not yet available
No reference posted for this study.